{"title": "Highly accurate and sensitive diagnostic detection of SARS-CoV-2 by digital PCR", "doi": "10.1101/2020.03.14.20036129", "citation_id": "2020.03.14.20036129v1", "date": "2020-03-18", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.14.20036129", "abstract": "<p>Background: The outbreak of COVID-19 caused by a novel Coronavirus (termed SARS-CoV-2) has spread to over 120 countries around the world. Currently, real-time qPCR (RT-qPCR) is used as the gold standard for diagnostics of SARS-CoV-2. However, the positive rate of RT-qPCR assay of pharyngeal swab samples is reported to be 30~60%. More accurate and sensitive methods are urgently needed. \nMethod\uff1aWe established a digital PCR (dPCR) protocol to detect SARS-CoV-2 on 194 clinical pharyngeal swab samples, including 103 suspected patients, 75 close contacts and 16 supposed convalescents. \nResults: The limit of blanks (LoBs) of the dPCR assays are about 1.6, 1.6 and 0.8 copies/reaction for ORF 1ab, N and E gene. The limit of detection (LoD) is 2 copies/reaction. The overall accuracy of ddPCR is 95.5 %. For the fever suspected patients, the accuracy of SARS-CoV-2 detection was significantly improved from 28.2% to 87.4% by dPCR. For close contacts, the suspect rate was greatly decreased from 21% down to 1%. In addition, quantification of the virus load for convalescents by dPCR showed that a longer observation in the hospital is needed for aged patients. \nConclusion: dPCR could be a confirmatory method for suspected patients diagnosed by RT-qPCR. Furthermore, dPCR is more sensitive and suitable for low virus load specimens from the both patients under isolation and those under observation who may not be exhibiting clinical symptoms.</p>", "twitter_description": "Background: The outbreak of COVID-19 caused by a novel Coronavirus (termed SARS-CoV-2) has spread to over 120 countries around the world. Currently, real-time qPCR (RT-qPCR) is used as the gold standard for diagnostics of SARS-CoV-2. However, the positive rate of RT-qPCR assay of pharyngeal swab samples is reported to be 30~60%. More accurate and sensitive methods are urgently needed. Method\uff1aWe established a digital PCR (dPCR) protocol to detect SARS-CoV-2 on 194 clinical pharyngeal swab samples, including 103 suspected patients, 75 close contacts and 16 supposed convalescents. Results: The limit of blanks (LoBs) of the dPCR assays are about 1.6, 1.6 and 0.8 copies/reaction for ORF 1ab, N and E gene. The limit of detection (LoD) is 2 copies/reaction. The overall accuracy of ddPCR is 95.5 %. For the fever suspected patients, the accuracy of SARS-CoV-2 detection was significantly improved from 28.2% to 87.4% by dPCR. For close contacts, the suspect rate was greatly decreased from 21% down to 1%. In addition, quantification of the virus load for convalescents by dPCR showed that a longer observation in the hospital is needed for aged patients. Conclusion: dPCR could be a confirmatory method for suspected patients diagnosed by RT-qPCR. Furthermore, dPCR is more sensitive and suitable for low virus load specimens from the both patients under isolation and those under observation who may not be exhibiting clinical symptoms.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Clinical Trial\n\nData collection of cases and close contacts were determined by the National Health Commission of the People\u0092s Republic of China to be part of a continuing public health outbreak investigation and were thus considered exempt from institutional review board approval. The analysis was performed on existing samples collected during standard diagnostic tests, posing no extra burden to patients.\n\n### Funding Statement\n\nFundamental Research Funds for Central Public welfare Scientific research Institutes sponsored by National Institute of Metrology, P.R. China (31-ZYZJ2001/AKYYJ2009)\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll relevant data are available upon request.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.14.20036129v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.14.20036129v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.14.20036129v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/18/2020.03.14.20036129.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.14.20036129v1", "access_rights": "restricted", "authors": ["lianhua dong", "Junbo Zhou", "Chunyan Niu", "Quanyi Wang", "Yang Pan", "Xia Wang", "Yongzhuo zhang", "Jiayi yang", "Manqing Liu", "Yang zhao", "Tao peng", "Jie xie", "yunhua gao", "Di wang", "yun zhao", "Xinhua Dai", "xiang fang"]}